Air Methods Reports 3Q2009 Results and 4Q2...(------- Total liabilities and stockho...),Health

Date:11/5/2009

------- Total liabilities and stockholders' equity $429,418 394,924 ======== ======= AIR METHODS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts) Three Months Nine Months Ended Ended September 30, September 30, ------------ ------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenue: Flight operations $131,723 131,079 370,917 370,298 Product operations 5,879 2,753 19,448 9,592 ----- ----- ------ ----- Total revenue 137,602 133,832 390,365 379,890 ------- ------- ------- ------- Expenses: Operating expenses 96,290 100,141 285,197 290,924 General and administrative 15,978 15,947 48,388 50,671 Gain on disposition of assets, net (239) (1,130) (772) (2,568) Depreciation and amortization 4,758 4,328 13,976 12,628 ----- ----- ------ ------ 116,787 119,286 346,789 351,655 ------- ------- ------- ------- Operating income 20,815 14,546 43,576 28,235 Interest expense (1,285) (1,270) (3,643) (3,943) Other, n
'/>"/>

SOURCE Air Methods Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
2. Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder
3. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
4. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
5. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs